The failure of Gossamer’s lead program in two Phase II trials continues to sow doubts about the efficacy of drug candidates targeting PTGDR2, but the company believes further analysis of one study’s data still points...

Three companies announced COVID-19 programs Monday aimed at blocking the excessive inflammatory response seen in severe cases. Alexion unveiled a global program for its C5 inhibitor Ultomiris, while 4D pharma moved its live biotherapeutic therapy...

The latest failure of asthma therapy fevipiprant from Novartis in two Phase III studies dimmed hopes for Gossamer’s lead program, which aims for the same target. Novartis AG (NYSE:NVS; SIX:NOVN) said Monday that pooled results...

Novartis is looking ahead to a second set of late-stage readouts next quarter for fevipiprant to treat asthma, despite the candidate’s failure to meet the primary endpoint in two Phase III studies. Along with its...

In the latest step toward breaking the barrier to identifying neoantigens displayed on MHCII, Neon has generated a systems biology model that outperforms publicly available predictors. The development brings immuno-oncology closer to personalized therapies directing...

A string of departures at Novartis AG and strategic shifts by new CEO Vasant Narasimhan have produced a fairly thorough makeover of the executive committee he inherited in 2018. The team gains a pipeline that...

ReNeuron gained 51p (30%) to 222p on Tuesday after it granted a Fosun subsidiary exclusive rights to develop and commercialize its hRPC and CTX stem cell therapies in China. ReNeuron Group plc (LSE:RENE) will receive...

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Feb. 7 . Gossamer was up $1.94 (12%) to $17.94 on its first day of trading Feb. 8. Launched officially just 13 months...

Gossamer Bio Inc. (NASDAQ:GOSS) raised $276 million in an upsized IPO priced late Thursday. Trading is to begin Friday. Launched officially just 13 months ago by ex-Receptos Inc. executives, Gossamer is developing therapeutics for inflammation,...